Abstracts tagged "dermatomyositis"

Abstract Number: 0816 • ACR Convergence 2024
Distinct Transcript and Protein Dysregulation Patterns in Dermatomyositis and Systemic Lupus Erythematosus
James Ward¹, Mythri Ambatipudi², Zerai Manna³, Michael Smith⁴, Melissa de los Reyes⁵, Adam Schiffenbauer⁶, Saifur Rahman⁷, Kamelia Zerrouki⁵, Fredrick Miller¹, Mariana Kaplan⁸, Jian-Liang Li¹, Kerry Casey⁹, Lisa Rider¹⁰ and Sarfaraz Hasni⁶, ¹National Institute of Environmental Health Sciences, NIH, Durham, NC, ²Harvard Medical School, Boston, MA, ³NIH, Bethesda, MD, ⁴Horizon Therapeutics, Alexandria, VA, ⁵AstraZeneca, Gaithersburg, MD, ⁶NATIONAL INSTITUTES OF HEALTH, Bethesda, MD, ⁷AstraZeneca, Gaithersburg, ⁸NIAMS/NIH, Bethesda, MD, ⁹Regeneron Pharmaceuticals, Terrytown, NY, ¹⁰NIEHS, NIH, Garrett Park, MD
Background/Purpose: Systemic lupus erythematosus (SLE) and dermatomyositis (DM) are hypothesized to be triggered by shared genetic and environmental factors leading to aberrant activation of innate…
Abstract Number: 1160 • ACR Convergence 2024
Short Form-36 Psychometric Properties in Idiopathic Inflammatory Myopathies: Reliability, Validity and Responsiveness
shiri keret¹, Anushka Aggarwal², Maha Almackenzie³, Tanya Chandra⁴, Raisa Silva⁵, Eugenia Gkiaouraki⁶, Nantakarn Pongtarakulpanit⁷, shreya Sriram⁶, Chester Oddis⁷ and Rohit Aggarwal⁸, ¹Rheumatology unit, Bnai-Zion medical center and the faculty of Medicine, Technion - Israel Institute of Technology, Haifa, Israel., Atlit, Israel, ²Department of Rheumatology, Indraprastha Apollo Hospital, New delhi, NY, ³Division of Rheumatology, Department of Medicine, Medical Cities of the Ministry of the Interior Riyadh, Saudi Arabia, Arlington, VA, ⁴University of Pittsburgh Medical Center, Pittsburgh, PA, ⁵Internal medicine, University of Pittsburgh Medical Center, Pittsburgh, PA, ⁶Division of Rheumatology and Clinical Immunology, University of Pittsburgh Medical Center, Pittsburgh, PA, ⁷Division of Rheumatology and Clinical Immunology, University of Pittsburgh, Pittsburgh, PA, ⁸Division of Rheumatology and Clinical Immunology, University of Pittsburgh, Pittsburgh, PA, USA, Pittsburgh, PA
Background/Purpose: The quality of life, as measured by the Short Form-36 (SF-36), is reduced in patients with idiopathic inflammatory myopathies (IIM). Although endorsed by the…
Abstract Number: 1732 • ACR Convergence 2024
In Vitro Screening of siRNAs Designed to Knockdown Interferon Beta as a Novel Therapeutic Approach for Treatment of Adult and Juvenile Dermatomyositis
Joanna Parkes, Andrés Correa-Sánchez, Mark Cunningham and Peter Oliver, MRC Nucleic Acid Therapy Accelerator, Didcot, United Kingdom
Background/Purpose: The main treatments for adult and juvenile dermatomyositis (DM/JDM) are immunosuppressant drugs and corticosteroids, which have significant side effects and are not effective in…
Abstract Number: 2624 • ACR Convergence 2024
Measuring Clinically Inactive Disease at One Year in Patients with Juvenile Dermatomyositis (JDM) in the Childhood Arthritis and Rheumatology Research Alliance (CARRA) Registry
Jessica Neely¹, Peter Shrader², Stacey Tarvin³, Kaveh Ardalan⁴, Susan Shenoi⁵, Adam Huber⁶, Susan Kim⁷ and Hanna Kim⁸, and for the CARRA Registry Investigators, ¹UCSF, San Francisco, CA, ²Duke Clinical Research Institute, Durham, NC, ³Indiana University School of Medicine, Indianapolis, IN, ⁴Duke University School of Medicine, Durham, NC, ⁵Seattle Children's Hospital and Research Center, Mercer Island, WA, WA, ⁶IWK Health Centre, Halifax, NS, Canada, ⁷University of California, San Francisco, CA, ⁸National Institute of Arthritis Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD
Background/Purpose: While remission off medication is the goal in JDM, timely achievement of clinically inactive disease (CID) is an important interim outcome. Data from the…
Abstract Number: 0831 • ACR Convergence 2024
JDM Proteomic Signature at Disease Onset and Progression Highlights Persistent Dysregulation of Cell Death, Redox and Innate Immune Signaling
Jessica Neely¹, Jeff Dvergsten², Zilan Zheng¹, Chioma Madubata³, Hanna Kim⁴, Sara Sabbagh⁵, Sophia Matossian⁶, Christine Goudsmit⁶, Celine Berthier⁶ and Jessica Turnier⁷, and for the CARRA Registry Investigators and Translational Medicine for Juvenile Myositis Working Group, ¹UCSF, San Francisco, CA, ²Duke University Hospital, Hillsborough, NC, ³University of California, San Francisco, San Francisco, CA, ⁴National Institute of Arthritis Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD, ⁵Medical College of Wisconsin, Milwaukee, WI, ⁶University of Michigan, Ann Arbor, MI, ⁷University of Michigan, Saline, MI
Background/Purpose: Juvenile dermatomyositis (JDM) patients frequently have incomplete response to therapy. We utilized exploratory proteomics to advance understanding of dysregulated proteins and biological pathways that…
Abstract Number: 1161 • ACR Convergence 2024
Characterization of the Clinical Presentation of Idiopathic Inflammatory Myopathies According to the Profile of Specific Autoantibodies with Multiple Positivity
Adriana Miguel-Álvarez¹, luis M Amezcua Guerra², María L Loredo-Mendoza¹, Luis H. Silveira Torre³ and Angélica Vargas Guerrero⁴, ¹Instituto Nacional de Cardiología "Ignacio Chávez", México, Distrito Federal, Mexico, ²Department of Immunology, Instituto Nacional de Cardiología Ignacio Chávez., México, Mexico, ³Department of Rheumatology , Instituto Nacional de Cardiología Ignacio Chávez., Mexico City, Mexico, ⁴Department of Rheumatology , Instituto Nacional de Cardiología Ignacio Chávez., México, Mexico
Background/Purpose: The aim of this study is to assess if there are clinical and serological differences in patients with idiopathic inflammatory myopathies (IIM) according to…
Abstract Number: 1736 • ACR Convergence 2024
Effectiveness and Safety of Tofacitinib vs. Calcineurin Inhibitor in Interstitial Lung Disease Secondary to Anti-Melanoma Differentiation-Associated Gene 5-Positive Dermatomyositis: A Multi-Center Cohort Study with Propensity Score-Based Inverse Probability of Treatment Weighting
Wanlong Wu¹, Bingpeng Guo², Wenjia Sun³, Dan Chen⁴, Wenwen Xu⁵, Zhiwei Chen⁵, Yakai Fu⁵, Yan Ye⁵, Xia Lyu⁶, Zhixin Xue⁵, Kaiwen Wang⁵, Jiangfeng Zhao⁷, Chunhua Ye⁵, Min Dai⁵, Wei Fan⁵, Jia Li⁵, Xiaodong Wang⁵, Yu Xue⁸, Weiguo Wan⁸, Li Sun⁴, Huaxiang Wu⁹, Qun Luo², Qian Han², Qiong Fu¹ and Shuang Ye¹, ¹Department of Rheumatology, Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China (People's Republic), ²State Key Laboratory of Respiratory Disease, National Clinical Center for Respiratory Disease, Guangzhou Institute of Respiratory Health, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, Guangdong, China (People's Republic), ³The Second Affiliated Hospital of Zhejiang University, School of Medicine, Hangzhou, Zhejiang, China (People's Republic), ⁴The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang, China (People's Republic), ⁵Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China (People's Republic), ⁶Department of Rheumatology, Renji Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, Shanghai, China (People's Republic), ⁷Department of Rheumatology, Jiading Branch, Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China (People's Republic), ⁸Department of Rheumatology, Huashan Hospital, Fudan University, shanghai, China (People's Republic), ⁹Department of Rheumatology, The Second Affiliated Hospital of Zhejiang University, Hangzhou, Zhejiang, China (People's Republic)
Background/Purpose: The current management of anti-melanoma differentiation-associated gene 5-positive dermatomyositis (MDA5+DM) is challenging and largely empirical rather than evidence-based. Small-sized proof-of-concept trial and case series…
Abstract Number: 2655 • ACR Convergence 2024
Diagnostic Challenges of Dermatomyositis: A Retrospective Study of Its Dermatologic Mimics and Misdiagnoses
Aaron Bao¹, Eleni Tiniakou², Lisa Christopher-Stine³, Christopher Mecoli³, Jemima Albayda¹, Julie Paik³, William Kelly⁴ and Jun Kang⁵, ¹Johns Hopkins School of Medicine, Baltimore, MD, ²Johns Hopkins University, Lutherville Timonium, MD, ³Johns Hopkins University, Baltimore, MD, ⁴Johns Hopkins University, Hillsboro, NH, ⁵Johns Hopkins University School of Medicine, Baltimore, MD
Background/Purpose: Dermatomyositis (DM) is often misdiagnosed due to its diverse clinical presentation. This study aimed to identify common dermatologic mimics of DM, characterize misdiagnosis rates…
Abstract Number: 0882 • ACR Convergence 2024
Brepocitinib, a Selective TYK2/JAK1 Inhibitor Under Evaluation for the Treatment of Dermatomyositis, Reduces Inflammatory Cytokine Signaling and Interferon-induced Apoptosis in Primary Human Epidermal Keratinocytes
Jiří Vencovský¹, Alexandra Goriounova², Lisa McConnachie² and Brendan Johnson², ¹Institute of Rheumatology and Department of Rheumatology, First Faculty of Medicine, Charles University, Prague, Czech Republic, ²Priovant Therapeutics, Durham, NC
Background/Purpose: Dermatomyositis (DM) is characterized by inflammatory and degenerative changes of skin and muscle and upregulation of Type I IFN-regulated gene and protein levels in…
Abstract Number: 1166 • ACR Convergence 2024
Characteristics, Treatments, and Outcomes of Patients with Dermatomyositis from Two Large, Nationwide US Cohorts
Michael George¹, Thomas Riley², Ellen Romich³, Bryant England⁴, Jessica Chung⁵, Karim Masri⁶, Shanette Daigle⁷, Emily Holladay⁸, Yujie Su⁹, Fenglong xie¹⁰ and Jeffrey Curtis¹¹, ¹University of Pennsylvania, Philadelphia, PA, ²Hopsital of the University of Pennsylvania, Philadelphia, PA, ³University of Pennsylvania, Media, PA, ⁴University of Nebraska Medical Center, Omaha, NE, ⁵Pfizer, New York, NY, ⁶Pfizer Inc, Collegeville, PA, ⁷FASTER, Birmingham, AL, ⁸University of Alabama at Birmingham, Edmond, OK, ⁹Illumination Health, Hoover, AL, ¹⁰University of Alabama at Birmingham; Illumination Health, Birmingham, AL, ¹¹Illumination Health, Birmingham, AL
Background/Purpose: Studies of dermatomyositis (DM) are frequently limited to single center cohorts at academic centers. We aimed to use two large nationally representative US cohorts…
Abstract Number: 1769 • ACR Convergence 2024
Top Peripheral Blood Transcriptomic Gene Modules Reveal Functional Annotation and Correlation with Clinical Traits in Juvenile Dermatomyositis (JDM) and Myositis-Specific Autoantibody (MSA) Groups
Ujana Zajmi¹, Megan Darrell¹, Amy Kaneshiro¹, Adeline Chin¹, Adriana Jesus², Stephen Brooks¹, Raphaela Goldbach-Mansky², Lisa Rider³ and Hanna Kim⁴, ¹NIH/NIAMS, Bethesda, MD, ²NIH/NIAD, Bethesda, MD, ³NIEHS, NIH, Garrett Park, MD, ⁴National Institute of Arthritis Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD
Background/Purpose: Myositis-specific autoantibody (MSA) subgroups define phenotypes associated with specific clinical traits and outcomes within JDM, a clinically heterogeneous autoimmune disease. The pathogenesis of JDM…
Abstract Number: PP08 • ACR Convergence 2024
Whispers of Resilience: Navigating Life with Rheumatism
Vinchelle Hardison and Vinchelle Hardison, Nationwide Children's Hospital, Columbus, OH
Background/Purpose: “What’s wrong with me mom? Why am I always slow and hurting? Why can’t I play without being in pain like the other kids?”…
Abstract Number: 0919 • ACR Convergence 2024
The Effects of CB2R Activation on Inflammatory Pathways in Dermatomyositis
Rohan Dhiman¹, Ahmed Eldaboush², Navin Vijayarangan³, Darae Kang³, Caroline Stone², Nilesh Kodali³, DeAnna Diaz³ and Victoria Werth⁴, ¹University of Pennsylvania, Newport Coast, CA, ²University of Pennsylvania, Philadelphia, PA, ³PennMedicine, Philadelphia, ⁴Hospital of the University of Pennsylvania, Philadelphia, PA
Background/Purpose: Previous in vitro investigations done by our group into the utility of CB2R activation to treat dermatomyositis (DM) used stimulants that activated pathways not…
Abstract Number: 1169 • ACR Convergence 2024
Efficacy of Intravenous Immunoglobulin (Octagam 10%) on Pulmonary Manifestations in Patients with Dermatomyositis: Results from the ProDERM Study
Rohit Aggarwal¹, christina Charles-Schoeman² and Joachim Schessl³, and the ProDERM Investigators, ¹Division of Rheumatology and Clinical Immunology, University of Pittsburgh, Pittsburgh, PA, USA, Pittsburgh, PA, ²UCLA Medical Center, Santa Monica, CA, ³Friedrch-Baur-Institut; Ludwig-Maximilians University of Munich, Munich, Germany
Background/Purpose: Interstitial lung disease (ILD) and other pulmonary manifestations are a major cause of mortality and morbidity in patients with dermatomyositis (DM). The ProDERM study…
Abstract Number: 1777 • ACR Convergence 2024
Broad Proteomic Analysis Reveals Top Differential Protein Modules and Functional Annotations with Clinical Traits in Juvenile Dermatomyositis (JDM) and Myositis-Specific Autoantibody (MSA) Groups
Amy Kaneshiro¹, Adeline Chin¹, Lisa Rider², Frederick Miller³, Foo Cheung⁴, Megan Darrell¹, Angelique Biancotto⁴, Ujana Zajmi¹ and Hanna Kim⁵, ¹NIH/NIAMS, Bethesda, MD, ²NIEHS, NIH, Garrett Park, MD, ³NIH, NIEHS, Chapel Hill, NC, ⁴NIH/NIAID, Bethesda, MD, ⁵National Institute of Arthritis Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD
Background/Purpose: JDM is a heterogenous systemic autoimmune disease with muscle and skin pathology, which can be clinically subgrouped by MSAs (ex: anti-TIF1, anti-MDA5 autoantibodies (Ab)).…

1
2
3
…
24
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].